Abstract
Homozygous familial hypercholesterolemia (HoFH) is an orphan disease caused by biallelic mutations at the LDL receptor (LDLR) gene, with a prevalence estimated at 1 : 250 000 to 1 : 630 000. HoFH is characterized by extremely elevated plasma levels of LDL-C greater than 10 mmol/l (>387 mg/dl), tendinous and cutaneous xanthomas in youth and premature atherosclerotic cardiovascular disease (ASCVD). The expected prevalence varies from country to country depending on the presence of founder effects, genetic probability and life expectancy. Untreated, HoFH is a fatal condition before age 30. Plasma levels of LDL-C are the major cause of mortality and the therapeutic target. Statin therapy led to a remarkable improvement in survival but is of limited use in loss-of-function LDLR gene variants or 'null' mutations. Inhibitors of PCSK9 are a useful adjunct in patients with LDLR mutations with residual activity. Extracorporeal LDL filtration has improved survival since its introduction three decades ago. Novel therapies, not dependent on a functioning LDLR include lomitapide and mipomersen, which decrease hepatic apolipoprotein B secretion, and evinacumab, directed at the angiopoietin like-3 protein (ANGPLT-3). Over the past 3-4 decades,...Continue Reading
References
Oct 12, 2011·Circulation·Frederick J RaalA David Marais
Jul 24, 2014·European Heart Journal·Marina CuchelUNKNOWN European Atherosclerosis Society Consensus Panel on Familial Hypercholesterolaemia
Jun 2, 2016·The Lancet. Diabetes & Endocrinology·Raul D SantosUNKNOWN International Atherosclerosis Society Severe Familial Hypercholesterolemia Panel
Feb 22, 2017·The Lancet. Diabetes & Endocrinology·Frederick J RaalEvan A Stein
Jul 19, 2017·Circulation·Dirk J BlomMarina Cuchel
Jul 21, 2017·The New England Journal of Medicine·Daniel GaudetG Kees Hovingh
Sep 20, 2017·European Journal of Preventive Cardiology·Robert LeipoldHelen Phillips
Nov 4, 2017·Atherosclerosis. Supplements·V J J SchettlerUNKNOWN Scientific Board of GLAR for the German Apheresis Working Group
Nov 7, 2017·European Heart Journal·Gilbert R ThompsonFrederick J Raal
Feb 6, 2018·Journal of Clinical Lipidology·Merel L HartgersClaudia Stefanutti
Feb 7, 2018·Atherosclerosis·Meral KayikciogluOsman Ilhan
Oct 12, 2018·Current Pharmaceutical Design·Thomas GossiosAsterios Karagiannis
Dec 12, 2018·Expert Opinion on Pharmacotherapy·Johnathon Seth Parham, Anne Carol Goldberg
Dec 18, 2018·Journal of Atherosclerosis and Thrombosis·Yasushi IshigakiShinichi Oikawa
Mar 17, 2019·Journal of Medical Genetics·Ricardo Rodriguez-Calvo, Luis Masana
Mar 27, 2019·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Saeideh HajighasemiAmirhossein Sahebkar
Apr 5, 2019·Expert Opinion on Drug Safety·Etienne KhouryDaniel Gaudet
May 2, 2019·Current Atherosclerosis Reports·Gilbert Thompson, Klaus G Parhofer
Jun 25, 2019·Journal of Atherosclerosis and Thrombosis·Hisashi MakinoMariko Harada-Shiba
Jul 1, 2019·Journal of Clinical Lipidology·Claudia StefanuttiJie Lin
Sep 16, 2019·The Canadian Journal of Cardiology·Ambuja BanerjeeJacques Genest
Sep 30, 2019·Atherosclerosis·Alison PottleDev Borunendra Nath Datta
Nov 7, 2019·The American Journal of Cardiology·Daniel GaudetEvan Stein
Citations
Jun 22, 2021·Biochimie·Stéphane OrlowskiEric Bruckert
Aug 26, 2021·Patterns·Shuting JinXiangxiang Zeng
Oct 23, 2021·Endocrine Reviews·Amanda J Berberich, Robert A Hegele